Clinical Trial Update: Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 trial of ABT-199 (GDC-199) in relapsed/refractory Waldenström macroglobulinemia completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• ABT-199 (GDC-199) (venetoclax)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Waldenstrom Macroglobulinemia | Phase 2 | Status: COMPLETED | Results posted: 2021-05-11